Targeted polytherapy in small cell sarcoma and its association with doxorubicin

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1458-1468

  Dumont, S N ^a,b   Yang, D ^c   Dumont, A G ^a   Reynoso, D ^c   Blay, J Y ^d   Trent, J C ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Cell line; Combination; Doxorubicin; Small cell sarcoma; Targeted therapy

Indexed keywords

ABACAVIR; ALVESPIMYCIN; CASPASE 3; CASPASE 7; DOXORUBICIN; LIPOCORTIN 5; PROPIDIUM IODIDE; SORAFENIB; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; EWING SARCOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MTS ASSAY; REDUCTION; RHABDOMYOSARCOMA CELL LINE; SARCOMA CELL LINE; SMALL CELL SARCOMA; STAINING;

EID: 84911967880     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.016     Document Type: Article

References (64)

1. Ambati S.R., Lopes E.C., Kosugi K., Mony U., Zehir A., Shah S.K., Taldone T., Moreira A.L., Meyers P.A., Chiosis G., Moore M.A. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol. Oncol. 2014, 8:323-336.
2. Armistead P.M., Salganick J., Roh J.S., Steinert D.M., Patel S., Munsell M., El-Naggar A.K., Benjamin R.S., Zhang W., Trent J.C. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007, 110:2293-2303.
3. Ban J., Bennani-Baiti I.M., Kauer M., Schaefer K.L., Poremba C., Jug G., Schwentner R., Smrzka O., Muehlbacher K., Aryee D.N., Kovar H. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res. 2008, 68:7100-7109.
4. Blandford M.C., Barr F.G., Lynch J.C., Randall R.L., Qualman S.J., Keller C. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the children's oncology group. Pediatr. Blood Cancer 2006, 46:329-338.
5. Blay J.Y., Van Glabbeke M., Verweij J., Van Oosterom A.T., Le Cesne A., Oosterhuis J.W., Judson I., Nielsen O.S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur. J. Cancer 2003, 39:64-69.
6. Bonin G., Scamps C., Turc-Carel C., Lipinski M. Chimeric EWS-FLI1 transcript in a Ewing cell line with a complex t(11;22;14) translocation. Cancer Res. 1993, 53:3655-3657.
7. Burger A.M. Telomerase in cancer diagnosis and therapy: a clinical perspective. BioDrugs Clinical Immunother. Biopharm. Gene Ther. 1999, 12:413-422.
8. Cain J.E., McCaw A., Jayasekara W.S., Rossello F.J., Marini K.D., Irving A.T., Kansara M., Thomas D.M., Ashley D.M., Watkins D.N. Sustained low-dose treatment with the histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells. Sarcoma 2013, 2013:608964.
9. Carlini F., Ridolfi B., Molinari A., Parisi C., Bozzuto G., Toccacieli L., Formisano G., De Orsi D., Paradisi S., Grober O.M., Ravo M., Weisz A., Arcieri R., Vella S., Gaudi S. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One 2010, 5:e14221.
10. Chou T.C. Preclinical versus clinical drug combination studies. Leuk. Lymp. 2008, 49:2059-2080.
11. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
12. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. FEBS 1981, 115:207-216.
13. Coulter D.W., Walko C., Patel J., Moats-Staats B.M., McFadden A., Smith S.V., Khan W.A., Bridges A.S., Deal A.M., Oesterheld J., Davis I.J., Blatt J. Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Antican. Drugs 2013, 24:415-421.
14. Dasari A., Gore L., Messersmith W.A., Diab S., Jimeno A., Weekes C.D., Lewis K.D., Drabkin H.A., Flaig T.W., Camidge D.R. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 2013, 31:115-125.
15. Davis R.J., Bennicelli J.L., Macina R.A., Nycum L.M., Biegel J.A., Barr F.G. Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. Hum. Mol. Genetics 1995, 4:2355-2362.
16. Deng Y., Chang S. Role of telomeres and telomerase in genomic instability, senescence and cancer. Lab Invest 2007, 87:1071-1076.
17. Dumont S.N., Araujo D.M., Munsell M.F., Salganick J.A., Dumont A.G., Raymond K.A., Linassier C., Patel S., Benjamin R.S., Trent J.C. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer med 2013, 2:553-563.
18. Ecke I., Petry F., Rosenberger A., Tauber S., Monkemeyer S., Hess I., Dullin C., Kimmina S., Pirngruber J., Johnsen S.A., Uhmann A., Nitzki F., Wojnowski L., Schulz-Schaeffer W., Witt O., Hahn H. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009, 69:887-895.
19. Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., Parkinson D.R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J.Clin. Oncol. 1993, 11:1269-1275.
20. Elmore L.W., Holt S.E. Telomerase inhibition as an adjuvant anticancer therapy: it is more than just a waiting game. Exp. Opinion Therap. Targets 2007, 11:427-430.
21. Felix C.A., Kappel C.C., Mitsudomi T., Nau M.M., Tsokos M., Crouch G.D., Nisen P.D., Winick N.J., Helman L.J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992, 52:2243-2247.
22. Gatta G., Van der Zwan J.M., Casali P.G., Siesling S., Dei Tos A.P., Kunkler I., Otter R., Licitra L., Mallone S., Tavilla A., Trama A., Capocaccia R. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer Oxf. Engl. 1990) 2011, 47:2493-2511.
23. Goldstein M., Meller I., Orr-Urtreger A. FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chrom. Cancer 2007, 46:1028-1038.
24. Hamelin R., Zucman J., Melot T., Delattre O., Thomas G. p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int. J. Cancer J. Int. du Cancer 1994, 57:336-340.
25. Hawkins D.S., Spunt S.L., Skapek S.X. Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas. Pediatr. Blood Cancer 2013, 60:1001-1008.
26. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
27. Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 1993, 53:5284-5288.
28. Kuhn T.S. La structure des révolutions scientifiques trad 1972, [de la 2e édition américaine]. Flammarion, Paris.
29. Le Cesne A., Cresta S., Maki R.G., Blay J.Y., Verweij J., Poveda A., Casali P.G., Balana C., Schoffski P., Grosso F., Lardelli P., Nieto A., Alfaro V., Demetri G.D. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur. J. Cancer 2012, 48:3036-3044.
30. Lesko E., Gozdzik J., Kijowski J., Jenner B., Wiecha O., Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells invitro and seeding into bone marrow invivo. Antican. Drugs 2007, 18:1173-1181.
31. Li Y., Li X., Fan G., Fukushi J., Matsumoto Y., Iwamoto Y., Zhu Y. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett. 2012, 320:14-22.
32. Li Y., Tanaka K., Fan X., Nakatani F., Li X., Nakamura T., Takasaki M., Yamamoto S., Iwamoto Y. Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. Cancer Lett. 2010, 294:57-65.
33. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
34. Mallet D. La médecine entre science et Existence Collection Espace Éthique 2007, 246. Vuilbert, Paris.
35. Martinelli S., McDowell H.P., Vigne S.D., Kokai G., Uccini S., Tartaglia M., Dominici C. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chrom. Cancer 2009, 48:975-982.
36. Martins A.S., Ordonez J.L., Garcia-Sanchez A., Herrero D., Sevillano V., Osuna D., Mackintosh C., Caballero G., Otero A.P., Poremba C., Madoz-Gurpide J., de Alava E. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: invitro and invivo study. Cancer Res. 2008, 68:6260-6270.
37. Morioka H., Yabe H., Morii T., Yamada R., Kato S., Yuasa S., Yano T. Invitro chemosensitivity of human soft tissue sarcoma. Anticancer Res. 2001, 21:4147-4151.
38. Mouridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., Van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, 23:1477-1483.
39. Muhlenberg T., Zhang Y., Wagner A.J., Grabellus F., Bradner J., Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009, 69:6941-6950.
40. Pacey S., Ratain M.J., Flaherty K.T., Kaye S.B., Cupit L., Rowinsky E.K., Xia C., O'Dwyer P.J., Judson I.R. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest. New Drugs 2011, 29:481-488.
41. Paulson V., Chandler G., Rakheja D., Galindo R.L., Wilson K., Amatruda J.F., Cameron S. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromos. Cancer 2011, 50:397-408.
42. Peng C.L., Guo W., Ji T., Ren T., Yang Y., Li D.S., Qu H.Y., Li X., Tang S., Yan T.Q., Tang X.D. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol. Ther. 2009, 8.
43. Pinedo H.M., Bramwell V.H., Mouridsen H.T., Somers R., Vendrik C.P., Santoro A., Buesa J., Wagener T., Van Oosterom A.T., Van Unnik J.A. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984, 53:1825-1832.
44. Reynolds C.P., Maurer B.J. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 2005, 110:173-183.
45. Reynoso D., Nolden L.K., Yang D., Dumont S.N., Conley A.P., Dumont A.G., Zhou K., Duensing A., Trent J.C. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol. Oncol. 2011, 5:93-104.
46. Riedel R.F. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?. Semin. Oncol. 2011, 38(Suppl 3):S30-S42.
47. Rosenberg A.R., Skapek S.X., Hawkins D.S. The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker. Cancer Epidemiol. Biomarkers Prev.: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012, 21:1012-1018.
48. Scrable H., Witte D., Shimada H., Seemayer T., Sheng W.W., Soukup S., Koufos A., Houghton P., Lampkin B., Cavenee W. Molecular differential pathology of rhabdomyosarcoma. Genes Chrom. Cancer 1989, 1:23-35.
49. Smith D.F., Whitesell L., Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 1998, 50:493-514.
50. Smith J.L., Riedel R.F. Emerging therapeutic targets for soft tissue sarcoma. Curr. Oncol. Rep. 2011, 13:350-358.
51. Sonnemann J., Dreyer L., Hartwig M., Palani C.D., Hong le T.T., Klier U., Broker B., Volker U., Beck J.F. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J.Cancer Res. Clin. Oncol. 2007, 133:847-858.
52. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J.Clin. Oncol. 2002, 20:2672-2679.
53. Stewart D.J., Kurzrock R. Cancer: the road to Amiens. J.Clin. Oncol. 2009, 27:328-333.
54. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J. Clin. 2010, 60:376-392.
55. Terry J., Lubieniecka J.M., Kwan W., Liu S., Nielsen T.O. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in invitro models. Clin. Cancer Res. 2005, 11:5631-5638.
56. Turc-Carel C., Aurias A., Mugneret F., Lizard S., Sidaner I., Volk C., Thiery J.P., Olschwang S., Philip I., Berger M.P., et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22) (q24;q12). Cancer Genet. Cytogen. 1988, 32:229-238.
57. Van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., Schoffski P., Aglietta M., Staddon A.P., Beppu Y., Le Cesne A., Gelderblom H., Judson I.R., Araki N., Ouali M., Marreaud S., Hodge R., Dewji M.R., Coens C., Demetri G.D., Fletcher C.D., Dei Tos A.P., Hohenberger P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
58. Van Glabbeke M., Van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for research and treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J.Clin. Oncol. 1999, 17:150-157.
59. Vincenzi B., Silletta M., Schiavon G., Frezza A.M., Del Vescovo R., Zobel B.B., Santini D., Dei Tos A.P., Tonini G. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Expert Opin. Invest. Drugs 2013, 22:1-7.
60. Wachtel M., Schafer B.W. Targets for cancer therapy in childhood sarcomas. Cancer Treat. Rev. 2010, 36:318-327.
61. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
62. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5:835-844.
63. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
64. Witt O., Milde T., Deubzer H.E., Oehme I., Witt R., Kulozik A., Eisenmenger A., Abel U., Karapanagiotou-Schenkel I. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr. 2012, 224:398-403.